Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Operating Leases: 2021-2024

Historic Operating Leases for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $6.0 million.

  • Krystal Biotech's Operating Leases rose 27.22% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 27.22%. This contributed to the annual value of $6.0 million for FY2024, which is 8.70% down from last year.
  • Latest data reveals that Krystal Biotech reported Operating Leases of $6.0 million as of FY2024, which was down 8.70% from $6.6 million recorded in FY2023.
  • Krystal Biotech's 5-year Operating Leases high stood at $8.9 million for FY2022, and its period low was $6.0 million during FY2024.
  • Moreover, its 3-year median value for Operating Leases was $6.6 million (2023), whereas its average is $7.2 million.
  • Per our database at Business Quant, Krystal Biotech's Operating Leases grew by 11.33% in 2022 and then dropped by 25.89% in 2023.
  • Over the past 4 years, Krystal Biotech's Operating Leases (Yearly) stood at $8.0 million in 2021, then rose by 11.33% to $8.9 million in 2022, then declined by 25.89% to $6.6 million in 2023, then decreased by 8.70% to $6.0 million in 2024.